Article Sidebar

Submitted
May 20, 2021
Published
May 20, 2021
Download
PDF
Statistic
Read Counter : 37 Download : 26

Main Article Content

Abstract

Increasingly, the field is recognizing the need to enable a closer collaboration of industry and academia to create a more efficient system for developing new drugs. In parallel with this, the world of drug discovery has seen the emergence of translational research as an alternative approach to the creation of new drugs, and there is growing support for the claim that this strategy may provide solutions to some of the woes of the pharmaceutical industry. Translational medicine and translational pharmacology have become terms increasingly used to describe the focus of applied pharmacological research to ultimately help patients. Yet, the number of effective medicines reaching the approval stage continues to decline. Drug discovery represents the first step in the creation of new drugs, and takes place in academic institutions, biotech companies, and large pharmaceutical corporations. With the rise of translational research these relationships are shifting and new hubs are emerging, as key players seek to pool the expertise necessary to generate new therapies by linking laboratory discoveries directly to unmet clinical needs.

Keywords

Translational Pharmacology Drug Discovery Applied Research

Article Details

How to Cite
Deepak K. Bharati, Bharat V. Dhokchawle, Savita J. Tauro, & Swati S. Rawat. (2021). Translational Pharmacology: New approach of drug discovery. International Journal of Research in Pharmacology & Pharmacotherapeutics, 3(2), 130-135. https://doi.org/10.61096/ijrpp.v3.iss2.2014.130-135
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. [1] C. Simone Fishburn: Translational research: the changing landscape of drug discovery, Drug Discovery Today, Volume 18, Numbers 9/10,May 2013
  2. [2] Cressey, D. (2011) Traditional drug-discovery model ripe for reform. Nature 471, 17–18
  3. [3] Maxmen, A. (2011) Translational research: the American way. Nature 478, S16–S18
  4. [4] Hamdam, J., et al., Safety pharmacology — Current and emerging concepts, Toxicol. Appl. Pharmacol. (2013), http:// dx.doi.org/10.1016/j.taap.2013.04.039
  5. [5] Sanchez-Serrano, I. (2006) Success in translational research: lessons from the development of bortezomib.
  6. Nat. Rev. Drug Discov. 5, 107–114
  7. [6] Wadman, M. (2010) NIH encourages translational collaboration with industry. Nat. Rev. Drug Discov. 9, 255–256
  8. [7] Cohen, A.F. (2010) Developing drug prototypes: pharmacology replaces safety and tolerability? Nat. Rev.
  9. Drug Discov. 9, 856–865
  10. [8] Fitzgerald, G. (2010) Drug development needs a new brand of science. Nature 468, 869
  11. [9] Arrowsmith, J, Phase II failures: 2008-2010. Nature Review [Drug Discovery] 10:May 2011
  12. [10] Rubio-Viqueria B and Hidalgo M, Mouse xenograft models for drug discovery in pancreatic cancer. Chapter 2 In Drug Discovery and Pancreatic Cancer H. Han, P. Grippo (eds.) Springer Science + Business Media LLC,p 29-49, 2010.
  13. [11] Invention Reinvented: McKinsey Perspectives on Pharmaceutical R&D, McKiney and Company, 2010
  14. [12] Khoury, M.J. et al. (2007) The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet. Med. 9, 665–674
  15. [13] Stahl, S.M. (2010) Psychiatric stress testing: novel strategy for translational psychopharmacology. Neuropsychopharmacology 35, 1413–1414
  16. [14] Sarkar, I.N. et al. (2011) Translational bioinformatics: linking knowledge across biological and clinical realms. J. Am. Med. Inform. Assoc. 18, 354–357
  17. [15] Wetmore, D.Z. and Garner, C.C. (2010) Emerging pharmacotherapies for neurodevelopmental disorders. J.
  18. Dev. Behav. Pediatr. 31, 564–581
  19. [16] Ledford, H. (2008), Translational research: the full cycle. Nature 453, 843–845
  20. [17] Woolf, S.H. (2008), The meaning of translational research and why it matters. JAMA 299, 211–213
  21. [18] Hurko, O, The uses of biomarkers in drug development. Ann.N.Y.Acad. Sci. 1180: 1–10, 2009
  22. [19] Reddick, W.E. et al. (2009) Voxel-based analysis of T2 hyperintensities in white matter during treatment of childhood leukemia. AJNR Am. J. Neuroradiol. 30, 1947–1954
  23. [20] Reddick, W.E. et al. (2005) A typical white matter volume development in children following craniospinal irradiation. Neuro-Oncol. 7, 12–19